Zetia Cost in Georgia 2026: Ezetimibe Prices, Medicaid Coverage, and Savings Options

What Does Ezetimibe Actually Cost in Georgia in 2026?

Generic ezetimibe 10 mg tablets run approximately $15 per month at Georgia retail pharmacies in 2026, and that figure drops further with GoodRx or manufacturer discount cards. The brand-name product Zetia carries a manufacturer list price near $380 per month, but almost no cash-pay patient should pay that amount given generic availability.

Ezetimibe lost patent exclusivity in 2017, and generic competition drove prices sharply lower across U.S. markets. The FDA's Orange Book lists multiple approved generic versions of ezetimibe 10 mg [1]. At large Georgia chain pharmacies including CVS, Walgreens, Kroger, and Publix, the 30-tablet generic supply typically lands between $12 and $20 without any coupon. Applying a GoodRx coupon at Publix Pharmacy in Atlanta, for example, frequently brings the price below $10.

The $380 list price applies only to brand Zetia and is relevant for patients whose commercial insurance plan places Zetia on a high-cost specialty or non-preferred tier. Even then, Merck's savings card program (discussed below) can cap out-of-pocket costs for eligible commercially insured patients. Georgia's average cash-pay figure of $15/month for the generic reflects real-world 2026 pricing confirmed across major Georgia chains.

Ezetimibe works by blocking intestinal cholesterol absorption through the Niemann-Pick C1-like 1 (NPC1L1) transporter [2]. It reduces LDL cholesterol by 15 to 25 percent as monotherapy and adds incremental LDL lowering when combined with statins. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by an absolute 2.0 percentage points over 7 years compared to simvastatin alone, with a mean LDL-C of 53.7 mg/dL in the combination arm versus 69.5 mg/dL in the monotherapy arm [3].

How Georgia Medicaid Covers Ezetimibe

Georgia Medicaid covers ezetimibe only for members with a type 2 diabetes diagnosis. General hyperlipidemia alone is not a covered indication under the current 2026 Georgia Medicaid preferred drug list (PDL).

Georgia operates its Medicaid program primarily through three managed care organizations: Amerigroup Georgia, Peach State Health Management, and WellCare of Georgia. Each MCO follows the state PDL, which restricts ezetimibe reimbursement to the T2D indication. A prescribing provider who documents a comorbid type 2 diabetes diagnosis may submit a claim successfully. For patients with hyperlipidemia but no T2D, the prescriber must file a prior authorization (PA) request demonstrating medical necessity, statin intolerance, or failure to reach guideline-recommended LDL targets. PA approval is not guaranteed and approval rates for non-T2D indications have been inconsistent under the current Georgia PDL cycle.

The American College of Cardiology and American Heart Association 2022 cholesterol guidelines recommend ezetimibe as a second-line agent when statin therapy alone does not achieve a sufficient LDL-C reduction, particularly in very-high-risk atherosclerotic cardiovascular disease patients [4]. Citing those guideline thresholds in a PA letter strengthens the medical-necessity argument, though coverage remains at the MCO's discretion.

For Georgia Medicaid members who cannot obtain coverage, the $15 generic cash price may be a more practical path than spending weeks on PA paperwork, depending on the clinical timeline. Georgia's PeachCare for Kids program, which covers children in families with incomes above Medicaid thresholds, follows a similar PDL structure with the same ezetimibe restriction.

Which Commercial Insurance Plans Cover Zetia in Georgia?

Most commercial plans in Georgia cover generic ezetimibe at Tier 1 or Tier 2, with copays ranging from $0 to $25 per month. Brand Zetia typically sits on Tier 3 or higher, producing copays of $50 to $150 per month or percentage-based coinsurance.

Georgia's largest commercial insurance carriers include Blue Cross Blue Shield of Georgia (Anthem), Aetna, Cigna, UnitedHealthcare, and Humana. Each uses a national formulary that places generic ezetimibe favorably because it is both clinically effective and cost-effective for the plan. A 2020 analysis published in JAMA found that ezetimibe's cost per quality-adjusted life year fell well within accepted thresholds when used in high-risk cardiovascular patients post-acute coronary syndrome [5].

Employer-sponsored plans in Georgia generally mirror the national formulary structure. Federal employee plans (FEHB) and Medicare Part D plans operating in Georgia each have their own formulary tiers. For Medicare Part D specifically, the Low Income Subsidy (LIS) program, also called Extra Help, may reduce the generic ezetimibe copay to $1 to $4 per month for qualifying beneficiaries [6].

For brand Zetia specifically, Merck offers a copay savings card that may reduce the out-of-pocket cost to $0 per month for eligible commercially insured patients, subject to an annual cap. The card does not apply to government-funded insurance including Medicare, Medicaid, or TRICARE. Georgia patients can enroll at Merck's Zetia savings program portal or ask their pharmacist to apply the card at the point of sale.

Is Compounded Ezetimibe Legal in Georgia?

Compounded ezetimibe is legal in Georgia when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. It is not available through 503B outsourcing facilities for individual prescriptions.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications for individual patients based on a licensed prescriber's order [7]. Georgia pharmacies holding a valid 503A license from the Georgia State Board of Pharmacy may compound ezetimibe for a specific patient when a prescriber identifies a legitimate clinical need, such as a formulation not commercially available (for example, a liquid suspension for a patient with swallowing difficulties) or a documented allergy to an excipient in the commercial tablet.

Compounding pharmacies in the HealthRX network that serve Georgia patients have reported dispensing compounded ezetimibe at costs approaching $0 per month when paired with specific telehealth membership programs. That figure reflects a cost structure distinct from retail pharmacy pricing and depends on the pharmacy's internal pricing model and any bundled membership fee already paid by the patient. Patients should confirm total all-in costs directly with the dispensing pharmacy before assuming zero out-of-pocket.

The FDA maintains that compounding is appropriate when there is a documented clinical reason not met by commercially available products [8]. Prescribers writing for compounded ezetimibe should document the specific clinical rationale in the patient chart to comply with both federal and Georgia state pharmacy law.

The HealthRX clinical team uses a three-step prescribing framework for Georgia patients seeking ezetimibe:

1. Confirm LDL-C target per ACC/AHA 2022 risk stratification [4].
2. Check commercial formulary tier or Medicaid indication eligibility before writing the prescription.
3. Route to generic retail (approximately $15/month), Merck savings card (brand Zetia if commercially insured), or 503A compounded option based on patient cost tolerance and clinical indication.

This framework reduces the average time to first fill for HealthRX Georgia patients by eliminating coverage surprises at the pharmacy counter.

Ezetimibe's Clinical Rationale: Why Georgia Providers Prescribe It

Ezetimibe is prescribed in Georgia primarily as an add-on to statin therapy when LDL-C targets are not met, and as monotherapy when statins are contraindicated or not tolerated. The drug's mechanism, selective inhibition of intestinal NPC1L1, is complementary to statins' hepatic HMG-CoA reductase inhibition.

The IMPROVE-IT trial published in the New England Journal of Medicine in 2015 remains the primary outcomes data supporting ezetimibe use. Among 18,144 patients stabilized after acute coronary syndrome, those randomized to simvastatin 40 mg plus ezetimibe 10 mg reached a median LDL-C of 53.7 mg/dL versus 69.5 mg/dL with simvastatin alone. The 7-year primary endpoint event rate was 32.7% in the combination group versus 34.7% with monotherapy, a statistically significant absolute risk reduction (P<0.001 for LDL-C reduction; P=0.016 for the composite cardiovascular endpoint) [3].

The ACC/AHA 2022 guideline on cholesterol management states: "In patients with clinical ASCVD in whom LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe therapy" [4]. That recommendation carries a Class IIa, Level of Evidence A rating.

Statin intolerance affects roughly 5 to 10 percent of patients in clinical practice, based on data from the SAMSON trial (N=60) and real-world registries [9]. For those patients, ezetimibe monotherapy produces average LDL-C reductions of 15 to 22 percent, less than a high-intensity statin but meaningful for patients who cannot tolerate any statin dose [10]. Georgia clinicians also combine ezetimibe with PCSK9 inhibitors (evolocumab, alirocumab) in very-high-risk patients who require LDL-C below 55 mg/dL, consistent with European Society of Cardiology 2019 dyslipidemia guidelines [11].

Ezetimibe's safety profile is favorable. The drug does not cause the myalgias associated with statins and has no clinically significant drug interactions via CYP450 pathways. The FDA label notes that bile acid sequestrants may reduce ezetimibe absorption, so the two should be dosed at least 2 hours apart [1].

How to Get the Cheapest Ezetimibe Price in Georgia

The lowest available price for most Georgia patients in 2026 is approximately $0 per month through a combination of telehealth membership and a 503A compounding pharmacy, or approximately $10 per month for the generic at Publix with a GoodRx coupon.

For patients who prefer a traditional retail pharmacy, the following hierarchy applies in 2026:

Generic ezetimibe with GoodRx at Publix or Kroger in Georgia typically runs $8 to $12 per month. The same generic without any coupon averages $15. CVS Caremark's own brand CarePass discount program may reduce the price further for enrolled members. Costco and Sam's Club pharmacies in Georgia typically price the 30-tablet generic supply at $10 to $14 for non-members and members alike, since Georgia law requires pharmacies to serve non-members for prescriptions.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists ezetimibe 10 mg at approximately $7 to $9 per month plus a $5 shipping fee. That platform does not require insurance and ships to Georgia addresses [12].

For commercially insured Georgia patients on brand Zetia, Merck's savings card can reduce monthly cost to $0, subject to a per-year cap of approximately $1,800 (card terms change annually; verify at the Merck savings card site). Patients with Medicare or Medicaid cannot use the manufacturer card, but they may qualify for Merck's patient assistance program (PAP) if income falls below 400% of the federal poverty level.

NeedyMeds.org and RxAssist.org both list ezetimibe-specific patient assistance programs for Georgia residents who are uninsured or underinsured [13]. Applications require proof of income, a completed prescriber certification, and a 90-day prescription.

Telehealth Prescribing of Ezetimibe in Georgia

Georgia allows telehealth prescribing of ezetimibe without a prior in-person visit, provided the clinician establishes a valid patient-physician relationship under Georgia telemedicine standards (O.C.G.A. Section 43-34-31).

Georgia adopted broad telemedicine practice standards that align with those published by the Federation of State Medical Boards. A Georgia-licensed physician or nurse practitioner may evaluate a patient's lipid panel, review cardiovascular risk, and prescribe ezetimibe via a synchronous video visit or an appropriate asynchronous protocol. The prescriber must document clinical findings sufficient to justify the prescription and must be available for follow-up [14].

HealthRX clinicians practicing in Georgia can prescribe ezetimibe 10 mg orally once daily during an initial telehealth visit when the patient provides recent lipid panel results and a completed cardiovascular history intake. The prescription routes to the patient's preferred Georgia pharmacy or, where appropriate, to a partnered 503A compounding pharmacy.

Controlled substances require in-person evaluation under both federal DEA rules and Georgia law. Ezetimibe is not a controlled substance, so no such restriction applies. The Ryan Haight Online Pharmacy Consumer Protection Act does not govern non-controlled medications, meaning telehealth prescribing of ezetimibe faces no federal prescription-mode restriction beyond the standard prescriber licensure requirement [15].

Patients in rural Georgia counties, where access to a lipidologist or cardiologist may require a 2 to 3 hour drive, benefit most from telehealth access. The CDC notes that rural Georgia counties have cardiovascular disease mortality rates up to 40 percent higher than urban Georgia counties [16]. Expanding telehealth access to lipid-lowering medications in these communities is a direct public-health application of existing Georgia telemedicine law.

Georgia-Specific Discount Programs for Ezetimibe

Beyond manufacturer and coupon programs, Georgia-specific resources exist for patients who need ezetimibe but face cost barriers.

The Georgia Department of Community Health operates the Drugs for the Uninsured program, which provides access to select medications at low or no cost through federally qualified health centers (FQHCs) across the state. Ezetimibe is included in the 340B drug pricing program that most Georgia FQHCs participate in, meaning patients seen at those centers may access ezetimibe at deeply discounted 340B prices [17]. Georgia has over 60 FQHC sites, concentrated in Atlanta, Savannah, Macon, and Augusta but present in rural counties as well.

The Georgia Chapter of the American Heart Association maintains a resource list for patients managing cardiovascular risk who face medication affordability challenges. That list references both the Merck PAP and community health center access points [18]. State-level legislative discussions in 2024 included proposals to expand Georgia Medicaid's PDL to cover lipid-lowering agents more broadly, though no statutory change has been enacted as of the 2026 PDL cycle.

Patients who are Georgia state employees or teachers may access the State Health Benefit Plan (SHBP), which covers generic ezetimibe at a $10 to $15 copay depending on the plan tier selected during open enrollment. Brand Zetia on the SHBP formulary typically sits at Tier 3 with a $50 to $75 copay, making the generic clearly preferable for most members.

Monitoring Ezetimibe Therapy in Georgia: What to Expect

After starting ezetimibe 10 mg once daily, a repeat fasting lipid panel at 6 to 8 weeks confirms the LDL-C response. Most patients see LDL-C fall by 15 to 22 percent from baseline on monotherapy, and by 20 to 25 percent incrementally when ezetimibe is added to an existing statin regimen [10].

Liver function tests are not routinely required before starting ezetimibe, unlike with statin initiation. The FDA label does not mandate baseline LFTs [1]. Georgia clinicians typically check a comprehensive metabolic panel at the initial cardiovascular risk assessment visit, which covers baseline hepatic function. Repeat LFTs are ordered only if symptoms suggest hepatotoxicity, which is rare with ezetimibe alone.

The 2022 ACC/AHA guideline recommends reassessing cardiovascular risk and LDL-C response every 3 to 12 months after any lipid-lowering medication change [4]. For very-high-risk patients (prior MI, stroke, or peripheral artery disease), a target LDL-C below 70 mg/dL is the standard; for extremely high-risk patients, the target may be below 55 mg/dL. If ezetimibe plus maximally tolerated statin does not achieve those targets, a PCSK9 inhibitor may be added. Evolocumab (Repatha) and alirocumab (Praluent) are both FDA-approved for this indication [19].

Georgia patients taking ezetimibe should inform their pharmacist and prescribing provider of any bile acid sequestrant use (cholestyramine, colesevelam) because these agents reduce ezetimibe absorption by approximately 55 percent when co-administered. Dosing ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant mitigates this interaction [1].

For a Georgia patient starting ezetimibe via HealthRX telehealth today, the standard clinical instruction is: take ezetimibe 10 mg orally once daily at the same time each day, obtain a fasting lipid panel at 6 to 8 weeks, and upload the result to your HealthRX patient portal for provider review. The follow-up visit confirms whether the LDL-C response meets your individualized ACC/AHA 2022 risk-stratified target.